Cancer therapy associated bone loss: Implications for hip fractures in mid-life women with breast cancer

Clinical Cancer Research

Volumn 17, Issue 3, 2011, Pages 560-568

  Edwards, Beatrice J ^a   Raisch, Dennis W ^b   Shankaran, Veena ^a   McKoy, June M ^a   Gradishar, William ^a   Bunta, Andrew D ^a   Samaras, Athena T ^a   Boyle, Simone N ^a   Bennett, Charles L ^c   West, Dennis P ^a   Guise, Theresa A ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEOXYCORTICOSTERONE ACETATE; DOXORUBICIN; EXEMESTANE; IBANDRONIC ACID; LETROZOLE; RISEDRONIC ACID; ROBANUL; TAMOXIFEN; TESTOSTERONE UNDECANOATE; UBEX; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE; BONE DENSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CLINICAL ASSESSMENT; EMBASE; FEMUR FRACTURE; FUNCTIONAL STATUS; HEALTH CARE; HIP FRACTURE; HOSPITAL SERVICE; HUMAN; MEDLINE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SHOPPING; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS; SURVIVORS;

EID: 79551715682     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1595     Document Type: Article

References (95)

1. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
2. Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ. Mortality risk after hip fracture. J Orthop Trauma 2003;17:53-6.
3. Caliri A, De Filippis L, Bagnato GL, Bagnato GF. Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007;49:21-7.
4. Brenneman SK, Barrett-Connor E, Sajjan S, Markson LE, Siris ES. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006;21:809-16. (Pubitemid 43787987)
5. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33. (Pubitemid 44607392)
6. Magaziner J, Hawkes W, Hebel JR, Zimmerman SI, Fox KM, Dolan M, et al. Recovery from hip fracture in eight areas of function. J Gerontol A Biol Sci Med Sci 2000;55:M498-507.
7. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J AmGeriatr Soc 2002;50: 1644-50. (Pubitemid 35192535)
8. Fink HA, Ensrud KE, Nelson DB, Kerani RP, Schreiner PJ, Zhao Y, et al. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteop Int 2003;14:69-76. (Pubitemid 36267903)
9. Keene GS, Parker MJ, GA P. Mortality and morbidity after hip fractures. BMJ 1993;307:1248-50.
10. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61.
11. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20. (Pubitemid 34441937)
12. Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial Efficacy and Safety Update Analyses. Cancer 2003;98:1802-10.
13. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
14. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57. (Pubitemid 43016814)
15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004:1081-92. (Pubitemid 38298988)
16. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-37. (Pubitemid 46224021)
17. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70.
18. Forbes J, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrazole and tamoxifen as adjuvant treatment for the treatment of early-stage breast cancer:100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
19. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus M. Secondary factors for bone loss in osteoporotic hip fractures. Osteoporos Int 2008;19:991-9.
20. Fitti JE, Kovar MG. The Supplement on aging to the 1984 National Health Interview Survey. Vital Health Stat 1987:1-115.
21. Nelson HD, Nevitt MC, Scott JC, Stone KL, Cummings SR. Smoking, alcohol, and neuromuscular and physical function of older women. Study of Osteoporotic Fractures Research Group. JAMA 1994;272: 1825-31. (Pubitemid 24374522)
22. Vogt MT, Cauley JA, Kuller LH, Nevitt MC. Functional status and mobility among elderly women with lower extremity arterial disease: the Study of Osteoporotic Fractures. JAm Geriatr Soc 1994;42:923-9. (Pubitemid 24280364)
23. Lin MY, Gutierrez PR, Stone KL, Yaffe K, Ensrud K, Fink HA, et al. Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc 2004;52:1996-2002. (Pubitemid 41725014)
24. Rodgers W, Miller B. A comparative analysis of ADL questions in surveys of older people. J Gerontol B Psychol Sci Soc Sci 1997;5221-36.
25. Kosorok MR, Omenn GS, Diehr P, Koepsell TD, Patrick DL. Restricted activity days among older adults. Am J Public Health 1992;82:1263-7.
26. Elston JM, Koch GG, Weissert WG. Regression-adjusted small area estimates of functional dependency in the noninstitutionalized American population age 65 and over. Am J Public Health 1991; 81:335-43.
27. Kleerekoper M. Evaluation of the patient with osteoporosis or at risk for osteoporosis. In:Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. Vol 2. San Diego: Academic Press; 2001:403-8.
28. Tannenbaum C, Clark J, Schwartzman KWallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributor to osteoporosis in otherwise healthy women. J Clin Endocr Metab 2002;87:4431-7. (Pubitemid 35247019)
29. Lin MY, Gutierrez PR, Stone KL, et al. Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Ger Soc 2004;52:1996-2002. (Pubitemid 41725014)
30. Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006;7:127-32. (Pubitemid 44044008)
31. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005;165:552-8. (Pubitemid 40344388)
32. Chen HF, Ho CA, Li CY. Increased risks of hip fracture in diabetic patients of Taiwan: a population-based study. Diabetes Care 2008;31:75-80.
33. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999;79:1179-81. (Pubitemid 29087894)
34. Vestergaard P, Rejnmark L, Mosekilde L. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int 2008;82:334-40.
35. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15:955-62. (Pubitemid 27106277)
36. Yonehara Y, Iwamoto I, Kosha S, Rai Y, Sagara Y, Douchi T. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients. J Obstet Gynaecol Res 2007;33:696-9. (Pubitemid 47383626)
37. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644-52.
38. Waltman NL, Twiss JJ, Ott CD, Gross GJ, Lindsey AM, Moore TE, et al. Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors. J Nurs Scholarsh 2003;35:333-8. (Pubitemid 38353203)
39. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008;14:6336-42.
40. Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 2008; 26:4289-95.
41. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85.
42. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010.
43. Writing Group for the ISCD. Position Development conference: indications and reporting for dual-energy X-ray absorptiometry. J Clin Densitom 2004;7:37-44.
44. Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, et al. NCCN task force report: bone health and cancer care. J Natl Compr Canc Netw 2006;4(Suppl 2):S1-20; quiz S21-22.
45. World Health Organization. FRAX WHO Fracture risk assessment tool. 2009.
46. National Osteoporosis Foundation. NOF's Clinician's Guide to Prevention and Treatment of Osteoporosis 2009.
47. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007;41:346-52.
48. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-8. (Pubitemid 350002882)
49. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008;26:4739-45.
50. Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19:1407-16.
51. Magaziner J, Fredman L, Hawkes W, Hebel JR, Zimmerman S, Orwig DL, et al. Changes in functional status attributable to hip fracture: a comparison of hip fracture patients to community-dwelling aged. Am J Epid 2003;157:1023-31. (Pubitemid 36628806)
52. Edwards BJ, Song JS, Dunlop D, Fink H. Functional decline after incident wrist fracture: the Study of Osteoporotic Fractures. Br Med J. 2010;341:c3324.
53. Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996;156:2469-75. (Pubitemid 26391477)
54. Greendale GA, Barrett-Connor E, Ingles S, Haile R. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc 1995;43:955-61.
55. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. Erratum in: (2004) J Clin Oncol 4022:1351.
56. Astra Zeneca labs. Arimidex, prescribing information. 2008.
57. Novartis Labs. Femara, prescribing information. 2008.
58. Pfizer Labs. Aromasin, prescribing information. 2008.
59. Medicines Evaluation Board in the Netherlands. Public Assessment Report:Zolkir 1 mg (generic Anastrozole). 2007.
60. Watch D. Evidence based recommendations: Anastrazole. 2006.
61. Portal fur Medizin and Gesundheit. Clinical experience for 'Arimidex' (anastrozole) passes two million patient years milestone. 2006.
62. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006;11:1121-31. (Pubitemid 44788404)
63. Canada Health. Arimidex: Letter to Health Care Professionals. 2004.
64. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001;16:97-103. (Pubitemid 32046193)
65. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996;11:676-85. (Pubitemid 26123919)
66. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153-64. (Pubitemid 30064426)
67. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.
68. Wainwright SA, Marshall LM, Ensrud K, Cauley J, Black D, Hillier TA, et al. Hip fracture in women without osteoporosis. J Clin Endocr Metab 2005;90:2787-93. (Pubitemid 40686325)
69. Schuit SC, Van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004;34:195-202. (Pubitemid 38142449)
70. Guo XE, Kim CH. Mechanical consequence of trabecular bone loss and its treatment: a three-dimensional model simulation. Bone 2002;30:404-11.
71. Legrand E, Chappard D, Pascaretti C, Duquenne M, Krebs S, Rohmer V, et al. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 2000; 15:13-9. (Pubitemid 30026927)
72. Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P. Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 2000;15:1368-75. (Pubitemid 30413870)
73. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics. CA Cancer J Clin 2004;54:8-29.
74. Cummings SR. Prevention of hip fractures in older women: a population-based perspective. Osteoporos Int 1998;8:S8-12.
75. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with nodepositive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20:4628-35. (Pubitemid 36025278)
76. Castiglione-Gertsch M, O'Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95:1833-46. (Pubitemid 38054684)
77. Miller WR. Aromatase inhibitors. Endocrine-related Cancer 1996;3: 65-79 (Pubitemid 26153380)
78. Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis- related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 2007;22:447-57. (Pubitemid 46797128)
79. Ray NF, Chan JK, Thamer M, Melton LJ, 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
80. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994;15:377-86. (Pubitemid 24168009)
81. Leech JA, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990;141:68-71. (Pubitemid 20023384)
82. Lombardi I Jr., Oliveira LM, Mayer AF, Jardim JR, Natour J. Evaluation of pulmonary function and quality of life in women with osteoporosis. Osteoporos Int 2005;16:1247-53. (Pubitemid 41396953)
83. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 4.03, 2010.
84. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Meeting highlights: International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 2005;16:1569-83. (Pubitemid 41511089)
85. Rieber AG, Theriault RL. Aromatase inhibitors in postmenopausal breast cancer patients. J Natl Compr Canc Netw 2005;3:309-14. (Pubitemid 44265437)
86. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-27. (Pubitemid 34831529)
87. Karnon J. Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness. Pharmacoeconomics 2006; 24:215-32. (Pubitemid 43374374)
88. Dunn C, Keam SJ. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Pharmacoeconomics 2006;24:495-517. (Pubitemid 43765218)
89. Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 2007;10:367-76. (Pubitemid 47485660)
90. Gil JM, Rubio-Terres C, Del Castillo A, Gonzalez P, Canorea F. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin Transl Oncol 2006;8:339-48.
91. Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006; 12:374-86. (Pubitemid 44063449)
92. Committee on cancer survivorship: Improving care and quality of life. Executive summary. In: Hewitt M GS, Stovall E, editors.From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press; 2005:1-14.
93. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 2006;33:S13-17.
94. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Executive summary. Osteoporos Int 1998;8:S3-S6.
95. WHO. FRAX WHO Fracture Risk Assessment Tool. 2008.